Francine Foss, MD, of Yale School of Medicine, discusses a phase II trial of the farnesyltransferase inhibitor tipifarnib for relapsed or refractory peripheral T-cell lymphoma published in Blood Advances.
The overall response rate was 40% and most patients responded within four months of treatment. The median duration of response was 3.7 months. Adverse events included cytopenias and bone marrow suppression.
“Tipifarnib was a very active drug in this study, even in patients with multiply refractory T-cell lymphoma,” Dr. Foss explained. “The drug is more active in the follicular helper subtype angioimmunoblastic T-cell lymphomas.”